Effect of Vitamin D Supplementation on Glutathione Peroxidase (GPx) Activity, Interleukin-6 (IL-6) Levels and Clinical Outcomes in Post-COVID-19 Patients - Trial NCT06419712
Access comprehensive clinical trial information for NCT06419712 through Pure Global AI's free database. This phase not specified trial is sponsored by Escuela Militar de Graduados de Sanidad, SEDENA and is currently Completed. The study focuses on Post-COVID19 Condition. Target enrollment is 54 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Escuela Militar de Graduados de Sanidad, SEDENA
Timeline & Enrollment
N/A
Nov 25, 2022
May 25, 2023
Primary Outcome
Glutathione Peroxidase (GPx) Activity,Neuropsychiatric Symptoms (Anxiety and Depression)
Summary
The goal of this clinical trial is to evaluate the effectiveness of vitamin D supplementation
 in treating neuropsychiatric symptoms and improving antioxidant levels in individuals
 diagnosed with post-COVID-19 condition, a state known as long-COVID. These individuals are
 primarily adults who have recovered from severe COVID-19 and exhibit persistent symptoms. The
 main questions it aims to answer are:
 
 Does vitamin D (cholecalciferol) supplementation decrease levels of anxiety and depression in
 patients with post-COVID-19 condition? Does vitamin D (cholecalciferol) supplementation
 increase glutathione peroxidase (GPx) activity in these patients? Researchers will compare
 the effects of daily versus bolus doses of vitamin D (cholecalciferol) to see if one method
 is more effective than the other in achieving sufficient vitamin D levels and improving
 clinical outcomes.
 
 Participants will:
 
 Be randomly assigned to receive either a daily dose or a bolus dose of vitamin D over an
 8-week period.
 
 Undergo blood tests to measure biochemical markers such as interleukin-6 (IL-6) and GPx
 before and two months after starting supplementation.
 
 Have their lung function tested using spirometry and diffusing capacity for carbon monoxide.
 
 Complete the Hospital Anxiety and Depression Scale to assess changes in anxiety and
 depression levels.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06419712
Non-Device Trial